Matthew Szot Sells 1,800 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock

Posted by Joseph Casey on Oct 16th, 2025

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) CFO Matthew Szot sold 1,800 shares of the company’s stock in a transaction on Monday, October 13th. The shares were sold at an average price of $14.07, for a total transaction of $25,326.00. Following the completion of the sale, the chief financial officer owned 13,533 shares of the company’s stock, valued at approximately $190,409.31. This trade represents a 11.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Cadrenal Therapeutics Stock Performance

Shares of Cadrenal Therapeutics stock opened at $14.06 on Thursday. The company has a market cap of $28.82 million, a P/E ratio of -1.58 and a beta of 0.96. Cadrenal Therapeutics, Inc. has a one year low of $8.74 and a one year high of $22.90. The firm has a fifty day moving average of $13.15 and a two-hundred day moving average of $13.68.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($1.87) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.27). As a group, equities analysts predict that Cadrenal Therapeutics, Inc. will post -7.59 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $32.00.

Check Out Our Latest Analysis on CVKD

Cadrenal Therapeutics Company Profile

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.